IMMX vs. SLRN, LRMR, OCGN, GNFT, INMB, MDWD, CTNM, FULC, MOLN, and CGEN
Should you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Acelyrin (SLRN), Larimar Therapeutics (LRMR), Ocugen (OCGN), Genfit (GNFT), INmune Bio (INMB), MediWound (MDWD), Contineum Therapeutics (CTNM), Fulcrum Therapeutics (FULC), Molecular Partners (MOLN), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry.
Immix Biopharma vs.
Acelyrin (NASDAQ:SLRN) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.
Immix Biopharma is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.
Acelyrin presently has a consensus target price of $9.60, indicating a potential upside of 269.23%. Immix Biopharma has a consensus target price of $7.00, indicating a potential upside of 297.73%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Acelyrin.
In the previous week, Acelyrin had 5 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Acelyrin and 0 mentions for Immix Biopharma. Acelyrin's average media sentiment score of 0.18 beat Immix Biopharma's score of 0.00 indicating that Acelyrin is being referred to more favorably in the media.
Acelyrin has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Acelyrin received 5 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 55.17% of users gave Acelyrin an outperform vote.
Acelyrin's return on equity of -44.12% beat Immix Biopharma's return on equity.
87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by company insiders. Comparatively, 48.9% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Acelyrin beats Immix Biopharma on 9 of the 15 factors compared between the two stocks.
Get Immix Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immix Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:IMMX) was last updated on 2/22/2025 by MarketBeat.com Staff
